Immunogenicity of a Live Dengue Vaccine (TAK-003).
Immunogenicity of a Live Dengue Vaccine (TAK-003).
复制标题
登革热活疫苗 (TAK-003) 的免疫原性。
DOI：
10.1093/infdis/jiac424
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
White,Laura
中科院分区：
文献类型：
--
作者：
deSilva,Aravinda;White,Laura
1. DeMaso CR, Karwal L, Zahralban-Steele M, et al. Specificity and breadth of the neutralizing antibody response to a live-attenuated tetravalent dengue vaccine. J Infect Dis 2022; 226: 1959–63. 2. Biswal S, Borja-Tabora C, Martinez Vargas L, et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. Lancet 2020; 395: 1423–33. 3. Tricou V, Low JG, Oh HM, et al. Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: a phase 2, double-blind, randomised, controlled trial. Vaccine 2020; 38: 1513–9.4. White LJ, Young EF, Stoops MJ, et al. Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003). PLoS Negl Trop Dis 2021; 15: e0009258. 5. Rivera L, Biswal S, Saez-Llorens X, et al. Three-year efficacy and safety
